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ABSTRACT
Objective: Identify characteristics of Kentucky community
pharmacists and community pharmacists’ practice
environment associated with utilization of the Kentucky All
Schedule Prescription Electronic Reporting Program
(KASPER).
Methods: Surveys were mailed to all 1,018 Kentucky
pharmacists with a KASPER account and an additional
1,000 licensed pharmacists without an account. Bivariate
analyses examined the association between KASPER
utilization and practice type (independent or chain) and
practice location (rural or urban). A multivariate Poisson
regression model with robust error variance estimated risk
ratios (RR) of KASPER utilization by characteristics of
pharmacists’ practice environment.
Results: Responses were received from 563 pharmacists
(response rate 27.9%). Of these, 402 responses from
community pharmacists were included in the analyses. A
majority of responding pharmacists (84%) indicated they
or someone in their pharmacy had requested a patient’s
controlled substance history since KASPER’s inception.
Bivariate results showed that pharmacists who practiced in
independent pharmacies reported greater KASPER
utilization (94%) than pharmacists in chain pharmacies
(75%; p<0.001). Multivariate regression results found
utilization of KASPER varied significantly among practice
environments of community pharmacists with those who
practiced in an urban location (RR: 1.11; [1.01–1.21]) or at
an independent pharmacy (RR: 1.27; [1.14–1.40]) having
an increased likelihood of KASPER utilization.
Conclusion: Utilization of KASPER differs by community
pharmacists’ practice environment, predominantly by
practice type and location. Understanding characteristics
of community pharmacists and community pharmacists’
practice environment associated with PDMP use is
necessary to remove barriers to access and increase
utilization thereby increasing PDMP effectiveness.
Keywords: Substance Abuse Detection; Adverse Drug
Reaction Reporting Systems; Mandatory Reporting;
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INTRODUCTION
The abuse and misuse of prescription drugs is a
major public health concern1 and characterized as
2
an epidemic in the US. In an effort to address the
problem of prescription drug abuse and diversion,
states have enacted legislation for the creation of
prescription drug monitoring programs (PDMPs) to
track controlled substance (CS) dispensing.3
Reports detailing a patient’s CS prescription history
can be accessed upon request, or proactively
distributed depending upon state regulations. As of
December 2013, PDMPs are operational in 48
states.4
In 1999, Kentucky implemented the Kentucky All
Schedule
Prescription
Electronic
Reporting
(KASPER)
program
allowing
prescribers,
pharmacists, and law enforcement officials to
request reports providing detailed information
regarding an individual’s CS prescription history. In
2005, a fully electronic version of KASPER was
launched allowing pharmacists and prescribers to
receive KASPER reports in real-time, permitting
them to utilize a patient’s CS prescription history to
make treatment decisions at the point of care.
Characteristics and opinions of healthcare
professionals who utilize PDMP reports have been
assessed. In Kentucky, satisfaction surveys
conducted in 2004, 2006, and 2010 captured
prescriber, dispenser, and law enforcement
opinions of KASPER.5-7 Results showed the
majority of KASPER users were satisfied with the
system and believed it to be effective, efficient,
accurate, and useful to identify CS abuse and
diversion. A 2010 study of Ohio community
pharmacists
examined
factors
influencing
enrollment in the state’s PDMP.8 Factors influencing
the decision to enroll were ability to assist in
decreasing doctor shopping and drug abuse,
Internet access, and receiving education about the
PDMP. A survey of Florida pharmacists assessing
attitudes regarding implementation of a PDMP
found that responding pharmacists agreed a PDMP
should be implemented and would reduce the
incidence of doctor shopping.9 Most recently, Green
and colleagues surveyed pharmacist users of
PDMPs in Connecticut and Rhode Island and
concluded pharmacists use PDMP data to screen
for abuse and doctor shopping, but PDMP use had
limited impact on other aspects of pharmacy
practice including counseling patients on safer
opioid use, and providing guidance on proper
10
storage and disposal of unused medications. The
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impact of practice setting was not assessed and
noted as being an important limitation to the study
as “practice setting may influence the frequency
with which pharmacists access PDMPs and how
PDMP information obtained is used”.10
Studies evaluating the effectiveness of PDMPs
suggest they successfully reduce the supply of
CS.11,12 This reduction in supply may not be
associated with improved health outcomes,
specifically reductions in drug overdose mortality
rates.13,14 However, some states with rigorous
PDMPs report recent reductions in overdose
15,16
and increasing evidence suggests that
mortality
utilization of PDMP reports reduces “doctor
shopping”.17 Because policies regarding access to
and utilization of PDMP reports by healthcare
4
providers vary among states , it is possible that
PDMP effectiveness is limited due to inadequate
use of PDMP reports at the point of care. A 2010
independent evaluation of the KASPER program
revealed 16% of licensed pharmacists and 27.5% of
licensed CS prescribers were registered with the
PDMP.18 These registration numbers parallel
estimates reported by other states, suggesting that
overall less than 25% of healthcare professionals
access PDMPs to obtain patient reports.19
Increased utilization of PDMP reports by healthcare
professionals, including pharmacists, could assist
PDMPs in meeting their stated objectives.
Understanding characteristics associated with
PDMP use may assist in developing strategies to
increase utilization, thereby increasing PDMP
effectiveness. The purpose of this study was to
examine the association between characteristics of
pharmacists and pharmacists’ practice environment
with KASPER use, and determine if specific
characteristics increased the likelihood of utilizing
KASPER.
METHODS
Survey
methodology
elicited
community
pharmacists’ perceptions regarding KASPER’s
impact on CS dispensing and effectiveness in
Kentucky in 2009. Survey items were developed by
health
policy
researchers
and
academic
pharmacists based on reviews of previous PDMP
5-7
surveys and discussions with KASPER staff. The
survey instrument was designed to take
approximately ten minutes to complete and was
pilot tested to verify clarity and length. All 1,018
Kentucky pharmacists with a KASPER account at
the time of the survey, and 1,000 additional
pharmacists without an account randomly selected
from a list of 6,600 actively licensed pharmacists in
Kentucky were contacted by mail to complete a 15item survey.
The survey packet included a postcard with a link to
an electronic version of the survey and an
identification code giving the pharmacist the option
of returning the survey via mail or completing it
online. Reminder postcards and second surveys
were sent two weeks after the initial mailing. Survey
protocol was approved by the Institutional Review

Board at the University of Kentucky and the
Kentucky Cabinet for Health and Family Services.
Bivariate analyses examined associations between
practice type (independent versus chain) and
practice location (rural versus urban) with
pharmacists
and
practice
environment
characteristics. Practice type classifications were
based on how the pharmacist described their
practice, with independent, chain, and supermarket
pharmacies considered community pharmacies. For
this analysis supermarket pharmacies were grouped
with chain pharmacies. Rural/urban classifications
were based on the 2003 Rural-Urban Continuum
(RUC) Codes developed by the US Department of
20
Agriculture. Counties with an RUC code of 1, 2, or
3 were grouped as urban while counties with an
20
RUC code of 4 or greater were considered rural.
Statistical significance was evaluated using the
Wald chi-square for categorical demographic data.
Data normality for continuous variables was tested
using the Shapiro-Wilk test and differences
assessed using the nonparametric Kruskal-Wallis
test.
A Poisson regression model using a robust error
variance
adjusting
for
characteristics
of
pharmacists’ practice environment, years since
licensure, daily CS dispensing volume, and
perceived effectiveness of KASPER estimated the
relative risk and associated confidence intervals (CI)
of KASPER utilization by community pharmacists.
For this study KASPER utilization was defined as
having requested information regarding a patient’s
CS prescription history since the inception of
KASPER. Covariates were hypothesized to predict
KASPER utilization (e.g., pharmacists with more
years since licensure less likely to use KASPER;
higher CS dispensing associated with greater
likelihood to utilize KASPER; perception of KASPER
being an effective tool associated with increased
likelihood of utilization). Statistical analyses were
conducted in Stata v12.0 (StataCorp LP, College
Station, TX). The a priori level of significance was
set at 0.05.
RESULTS
Descriptive and Bivariate
Surveys were mailed to 2,018 pharmacists in
Kentucky of which 563 were returned (response
rate 27.9%). Thirteen returned surveys were
deemed incomplete and removed from further
analysis. Another 26 observations were excluded
because the respondent indicated they practiced
outside Kentucky, and 120 were excluded because
the pharmacist did not specify their practice type as
a
community
pharmacy.
Two
additional
observations were excluded because the question
pertaining to KASPER use was not answered.
Overall, 402 observations were included in the
analyses.
Of the responding pharmacists, 339 (84%) indicated
they or personnel in their pharmacy had requested
a patient’s CS prescription history from KASPER
since the inception of the program. Among the
pharmacists who had not requested CS prescription
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Table 1. Baseline Characteristics of Community Pharmacists by Practice Type and Practice Location
Practice Type
Practice Location
Variable
Independent
Chain
Rural
Urban
p-value
N= 200
N = 202
N = 173
N = 217
KASPER Utilization
Requested Reports
187
94%
152
75%
<0.001*
145
84%
183
84%
Practice Location
Rural
115
58%
58
29%
<0.001*
Urban
75
38%
142
70%
<0.001*
Practice Type
Independent
115
66%
75
34%
Chain
58
33%
142
65%
Years in Practice
a
Median Years (IQR)
27
16(35)
15
5(29)
<0.001*
24
10(34)
19
8(31)
CS Dispensing Behavior
a
Median CS dispensed per day (IQR)
40
22(60)
50
30(100)
<0.001*
50
25(75)
45
26(75)
Perceived Effectiveness of KASPER
Reducing Drug Abuse and Diversion
176
88%
184
91%
0.219
148
86%
201
93%
Reducing Doctor Shopping
172
86%
174
86%
0.675
149
86%
186
86%
a
* Denotes statistical significance at the 5% level. IQR: Interquartile range

p-value
0.890
<0.001*
<0.001*
0.028*
0.391
0.042*
0.734

histories, the most common reason identified for not
using KASPER was “I do not have Internet access
to request KASPER reports at my practice site”
(n=30). All pharmacists who indicated lack of
Internet access as the primary barrier to using
KASPER identified their practice type as chain
pharmacy. Baseline characteristics and KASPER
utilization for responding pharmacists by practice
type (independent and chain) and practice location
(rural and urban) are presented in Table 1.

Bivariate comparisons revealed no significant
association between practice location and KASPER
use (p=0.878). Pharmacists in rural locations,
compared to urban locations, were more likely to
practice in an independent pharmacy (66% vs. 34%,
p<0.001), and also reported being licensed for a
longer period of time (median: 24, IQR: 10–34,
median: 19, IQR: 8–31, p=0.037).

A significant relationship was found in the bivariate
comparison between use of KASPER and practice
type, with a greater proportion of independent
pharmacists having utilized KASPER (94%) than
chain pharmacists (75%, p<0.001). Daily CS
dispensing volume varied significantly with chain
pharmacies dispensing more CS per day (median:
50, IQR: 30–100) than independent pharmacies
(median: 40, interquartile range (IQR): 22–60,
p=<0.001). Seventy percent (70%) of chain
pharmacists stated they practiced in an urban
location while only 38% of independent pharmacists
indicated they practiced in an urban location
(p<0.001). Responding pharmacists at independent
pharmacies reported being licensed for more years
(median: 27, IQR: 16–35) than chain pharmacists
(median: 15, IQR: 5–29, p<0.001), respectively.

Multivariate Poisson Regression Model

Responding pharmacists perceived KASPER as an
effective tool to reduce drug abuse and diversion
(92%; n=365) as well as doctor shopping (90%;
n=350) in Kentucky. No difference in perceived
effectiveness based on practice type was observed,
however, a greater proportion of pharmacists in
urban locations viewed KASPER as an effective tool
to reduce drug abuse/diversion than pharmacists in
rural locations (93% vs. 86%, p=0.041).

Results from the Poisson regression model are
presented in Table 2. Adjusted for the covariates
listed in Table 2, community pharmacists in urban
locations were 11% more likely to utilize KASPER
than pharmacists in rural locations (p=0.032). After
adjusting
for
the
covariates,
independent
pharmacists were 27% more likely to utilize

Table 2. Predicting Community Pharmacist Use of KASPER (Poisson regression model)
Variables
Relative Risk
p-value
95%CI
Practice Location
Rural
Ref
Urban
1.11*
0.037
1.01-1.21
Practice Site
Chain
Ref
Independent
1.27*
<0.001
1.15 - 1.40
Years in Practice
a
c
Years
0.96*
0.050
0.93 - 1.00
CS Dispensing Behavior
b
c
CS Dispensed per Day
1.00
0.297
1.00 - 1.01
Perceived PDMP Effectiveness Reducing Drug Abuse and Diversion
Ineffective
Ref
Effective
1.06
0.580
0.87 – 1.28
Perceived PDMP Effectiveness Reducing Doctor Shopping
Ineffective
Ref
Effective
1.12
0.224
0.93 – 1.36
*Denotes statistical significance at the 5% level
a
Years was divided by 10 to show the impact of practicing an additional 10 years
b
CS dispensed per day was divided by 10 to show the impact of dispensing an additional 10 CS per day
c
Confidence interval includes 1.00 due to rounding
95%CI = 95% Confidence Interval
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KASPER than chain pharmacists (p<0.001). A
negative relationship was observed between the
years since licensure and the likelihood of a
pharmacist using KASPER (p=0.05). Neither CS
dispensing volume nor perceived KASPER
effectiveness influenced the likelihood of KASPER
utilization.

by improvements to the system, changes in
corporate policies, and an increased awareness of
the program. To protect anonymity extensive
individual/pharmacist
level
questions
(i.e.
demographics) were not asked. Also, due to the
cross-sectional design of this study an association
between variables does not imply causality.

DISCUSSION

CONCLUSIONS

Prescription drug monitoring programs have been
implemented by states to address the prescription
drug abuse crisis in the US. This study’s purpose
was to examine the association between
characteristics of community pharmacists and
pharmacists’ practice environment with KASPER
use, and determine if specific characteristics
increased the likelihood of KASPER utilization. After
controlling for confounding covariates, our
multivariate results indicate that pharmacists who
practiced in urban locations or at independent
pharmacies were more likely to utilize KASPER
than their counterparts in rural locations or chain
pharmacies. The finding that urban pharmacists
were more likely to utilize KASPER than rural
pharmacists is somewhat surprising as prescription
drug abuse is most prevalent in rural areas.21-23 The
high prevalence of prescription drug abuse in rural
areas may also explain why the bivariate analysis
found a lower proportion of rural pharmacists
perceived KASPER as an effective tool to reduce
drug abuse and diversion. However, pharmacists’
perceptions concerning the effectiveness of
KASPER did not impact the likelihood of utilization
in the multivariate analysis.

Utilization of KASPER at the point of dispensing
varied significantly among community pharmacists
and was influenced by characteristics of
pharmacists’
practice
environment
including
practice type and practice location. For PDMPs to
meet their objectives of curbing CS abuse and
diversion, increased utilization of reports by
healthcare professionals, including community
pharmacists, for treatment decisions is warranted.
Understanding characteristics associated with
PDMP use may assist in developing strategies to
remove barriers and increase utilization, thereby
increasing the effectiveness of PDMPs.

Lack of Internet access was cited as the primary
reason for not requesting a KASPER report and is
consistent with previous surveys.8,10 Considering
that all responding pharmacists who indicated lack
of Internet access as the primary reason for not
using KASPER were chain pharmacists, it is not
surprising that chain pharmacists were less likely to
use KASPER. In fact, it is possible that this factor
(i.e., lack of Internet access) may outweigh the
impact of location and years-of-practice. Although
not specifically addressed in this survey, workflow
issues and corporate policies within chain
pharmacies are likely different from those in
pharmacies independently owned and operated.
Thus, to increase PDMP utilization, other barriers in
chain pharmacies should be explored.
The response rate of 27.9% is considered low,
though
consistent
with
other
pharmacist
8,10,24
The study sample may not be
surveys.
representative of all community pharmacists in
Kentucky as views of respondents may differ from
non-responders and pharmacists familiar with
KASPER may have been more inclined to
participate. Due to the anonymous nature of the
survey, comparisons of responders and nonresponders were not possible. Additionally, the
sample was limited to Kentucky community
pharmacists and may not be generalizable to other
states. This study analyzed a survey administered
in 2009 and current KASPER utilization by Kentucky
community pharmacists may have been impacted
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UTILIZACIÓN DEL PROGRAMA DE
MONITORIZACIÓN DE LA PRESCRIPCIÓN DE
MEDICAMENTOS EN LAS FARMACIAS
COMUNITARIAS DE KENTUCKY
RESUMEN

Objetivo: Identificar las características de las farmacias
comunitarias y del entorno de práctica de las farmacias
comunitarias relacionadas con la utilización del
Kentucky All Schedule Prescription Electronic Reporting
Program (KASPER).
Métodos: Se enviaron cuestionarios a todos los 1.018
farmacéuticos con cuenta en el KASPER y a un total
adicional de 1.000 farmacéuticos sin cuenta. Se examinó
la asociación entre la utilización de KASPER y el tipo de
ejercicio (independiente o de cadena) la localidad (rural o
urbana) con análisis bivariado. Mediante un modelo de
regresión multivariada de Poisson con varianza de error
robusta se estimaron los ratios de riesgo (RR) de la
utilización de KASPER con las características del
entorno de práctica de los farmacéuticos.

www.pharmacypractice.org (ISSN: 1886-3655)

4

Wixson SE, Blumenschein K, Goodin AJ, Talbert J, Freeman PR. Prescription drug monitoring program utilization in
Kentucky community pharmacies. Pharmacy Practice 2015 Apr-Jun;13(2):540.

Resultados: Se recibieron respuestas de 563
farmacéuticos (tasa de respuesta 27,9%). De esos, 402
respuestas de farmacéuticos comunitarios se incluyeron
en el análisis. La mayoría de los respondentes (84%)
indicó que ellos o alguien de su farmacia habían
solicitado una historia de substancias controladas de un
paciente desde que se creó KASPER. El análisis
bivariado demostró que los farmacéuticos que ejercían en
farmacias independientes comunicaban una mayor
utilización de KASPER (94%) que los farmacéuticos de
cadenas (75%; p<0,001). Los resultados de la regresión
multivariada encontraron que la utilización de KASPER
variaba significativamente entre los entornos de práctica
de los farmacéuticos comunitarios que trabajaban en
localidades urbanas (RR: 1,11; [1,01–1,21]) o los de
farmacias independientes (RR: 1,27; [1,14–1,40]) que
tenían una mayor probabilidad de utilización de
KASPER.

Conclusión: La utilización de KASPER difiere en los
ambientes de práctica de los farmacéuticos comunitarios,
principalmente por tipo de establecimiento y
localización. Es necesario entender las características de
los farmacéuticos comunitarios y de los entornos de
práctica de las farmacias comunitarias asociadas con el
uso de programas de monitorización de la prescripción
(PDMP) para eliminar las barreras de acceso y aumentar
la utilización incrementando así la efectividad del PDMP.
Palabras clave: Detección de Abuso de Sustancias;
Sistemas de Registro de Reacción Adversa a
Medicamentos; Notificación Obligatoria; Servicios de
farmacias comunitarias; Ejercicio profesional;
Medicamentos bajo Prescripción; Estados Unidos
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